Bioheart, Inc. Announces Additional Funding Support

    SUNRISE, Fla., Aug. 21 /CNW/ -- Bioheart, Inc., (Nasdaq:   BHRT) a company
committed to delivering intelligent devices and biologics that help monitor,
diagnose and treat heart failure and cardiovascular diseases, today announced
receipt of a $1 million unsecured loan from Rogers Telecommunications Limited.
 This loan is payable upon the later of three months or Bioheart's repayment
of its loan from BlueCrest Capital.  In addition, under certain circumstances,
the Company may be permitted to pay outstanding interest and principal in
shares of its common stock.  The loan will be used for Bioheart's ongoing
clinical and business operations, as the Company continues to actively pursue
additional investment support.
    "We are grateful for the support offered by Rogers Telecommunications
Limited and its recognition of the important clinical work we are doing for
heart failure patients," said Howard J. Leonhardt, Chairman and Chief
Executive Officer of Bioheart, Inc. "We hope to soon introduce intelligent
devices that offer synergies with our clinical therapies and provide critical
at-home monitoring of these patients."
    Bioheart recently announced its plan to enter the device market as a
complement to its MyoCell(R) Clinical Therapy program, which targets patients
with congestive heart failure.
    -- On August 1, 2008, the Company announced it entered into a non-binding
letter of intent to acquire MEDICALGORITHMICS, Ltd. and the worldwide rights
to the POCKETECG, a real-time wireless beat-to-beat, intelligent heart monitor
and diagnostic system, designed for long-term, fully-automated
electrocardiogram (ECG) arrhythmia and AFib analysis.  The device,
manufactured by MEDICALGORITHMICS, Ltd., Poland, recently received CE mark
approval for marketing throughout Europe.
    -- On July 10, 2008 the Company announced that it secured worldwide
non-exclusive distribution rights to the Bioheart 3370 Heart Failure Monitor,
an interactive and simple-to-use at-home intelligent device designed
specifically to improve available healthcare to patients outside hospitals who
are suffering from heart failure. The device, manufactured by RTX Healthcare
A/S (Denmark), has 510(k) market clearance from the U.S. Food and Drug
Administration for marketing in the U.S. and CE mark approval for marketing in
Europe and other countries that follow this mark.
    About Bioheart, Inc.:
    Bioheart, Inc. (Nasdaq:   BHRT) is committed to delivering intelligent
devices and biologics that help monitor, diagnose and treat heart failure and
cardiovascular diseases. Its goals are to improve a patient's quality of life
and reduce health care costs and hospitalizations. Specific to biotechnology,
Bioheart is focused on the discovery, development and, subject to regulatory
approval, commercialization of autologous cell therapies for the treatment of
chronic and acute heart damage. Its lead product candidate, MyoCell(R), is an
innovative clinical muscle-derived stem cell therapy designed to populate
regions of scar tissue within a patient's heart with new living cells for the
purpose of improving cardiac function in chronic heart failure patients. The
Company's pipeline includes multiple product candidates for the treatment of
heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose
tissue-derived stem cell treatment for acute heart damage, and MyoCell(R)
SDF-1, a therapy utilizing autologous cells that are genetically modified to
express additional potentially therapeutic growth proteins. For more
information on Bioheart, visit
    MyoCell, MyoCell SDF-1 and MyoCath are trademarks of Bioheart, Inc.
    Forward-Looking Statements:
    Except for historical matters contained herein, statements made in this
press release are forward-looking and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. Without
limiting the generality of the foregoing, words such as "may", "will", "to",
"plan", "expect", "believe", "anticipate", "intend", "could", "would",
"estimate", or "continue" or the negative other variations thereof or
comparable terminology are intended to identify forward-looking statements.
    Investors and others are cautioned that a variety of factors, including
certain risks, may affect our business and cause actual results to differ
materially from those set forth in the forward-looking statements. These risk
factors include, without limitation, (i) our ability to secure additional
financing; (ii) the timely success and completion of our clinical trials;
(iii) the occurrence of any unacceptable side effects during or after
preclinical and clinical testing of our product candidates; (iv) regulatory
approval of our product candidates; (v) our dependence on the success of our
lead product candidate; (vi) our inability to predict the extent of our future
losses or if or when we will become profitable; (vii) our ability to protect
our intellectual property rights; and (viii) intense competition. The Company
is also subject to the risks and uncertainties described in its filings with
the Securities and Exchange Commission, including the section entitled "Risk
Factors" in its Annual Report on Form 10-K for the year ended December 31,
2007, as amended by Amendment No. 1 on Form 10-K/A and its quarterly reports
on Form 10-Q for the quarters ended March 31, 2008 and June 30, 2008.

     Contact:  William Kline                  Lytham Partners, LLC
               Chief Financial Officer        Joe Diaz
               Nicholas Burke                 Joe Dorame
               VP - Financial Operations      Robert Blum
               (954) 835-1500                 (602) 889-9700


For further information:

For further information: William Kline, Chief Financial Officer, or
Nicholas Burke, VP - Financial Operations, both of Bioheart, Inc.,
+1-954-835-1500; or Joe Diaz, Joe Dorame, or Robert Blum, all of Lytham
Partners, LLC, +1-602-889-9700, for Bioheart, Inc. Web Site:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890